These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 2257308

  • 1. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.
    Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER, Hider RC.
    Blood; 1990 Dec 01; 76(11):2389-96. PubMed ID: 2257308
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice.
    Porter JB, Hoyes KP, Abeysinghe RD, Brooks PN, Huehns ER, Hider RC.
    Blood; 1991 Nov 15; 78(10):2727-34. PubMed ID: 1824264
    [Abstract] [Full Text] [Related]

  • 3. In vivo evaluation of hydroxypyridone iron chelators in a mouse model.
    Gyparaki M, Porter JB, Hirani S, Streater M, Hider RC, Huehns ER.
    Acta Haematol; 1987 Nov 15; 78(2-3):217-21. PubMed ID: 3120475
    [Abstract] [Full Text] [Related]

  • 4. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
    Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L.
    Am J Hematol; 1993 Apr 15; 42(4):340-9. PubMed ID: 8493983
    [Abstract] [Full Text] [Related]

  • 5. Dose response studies using desferrioxamine and orally active chelators in a mouse model.
    Kontoghiorghes GJ.
    Scand J Haematol; 1986 Jul 15; 37(1):63-70. PubMed ID: 3764334
    [Abstract] [Full Text] [Related]

  • 6. Protoporphyria induced by the orally active iron chelator 1,2-diethyl-3-hydroxypyridin-4-one in C57BL/10ScSn mice.
    Smith AG, Clothier B, Francis JE, Gibbs AH, De Matteis F, Hider RC.
    Blood; 1997 Feb 01; 89(3):1045-51. PubMed ID: 9028337
    [Abstract] [Full Text] [Related]

  • 7. Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo models.
    Huehns ER, Porter JB, Hider RC.
    Hemoglobin; 1988 Feb 01; 12(5-6):593-600. PubMed ID: 3209401
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
    Chenoufi N, Hubert N, Loréal O, Morel I, Pasdeloup N, Cillard J, Brissot P, Lescoat G.
    J Hepatol; 1995 Aug 01; 23(2):166-73. PubMed ID: 7499788
    [Abstract] [Full Text] [Related]

  • 9. Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.
    Yokel RA, Meurer KA, Hong CB, Dickey KM, Skinner TL, Fredenburg AM.
    Drug Metab Dispos; 1997 Feb 01; 25(2):182-90. PubMed ID: 9029049
    [Abstract] [Full Text] [Related]

  • 10. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
    Selig RA, White L, Gramacho C, Sterling-Levis K, Fraser IW, Naidoo D.
    Cancer Res; 1998 Feb 01; 58(3):473-8. PubMed ID: 9458092
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values.
    Liu ZD, Piyamongkol S, Liu DY, Khodr HH, Lu SL, Hider RC.
    Bioorg Med Chem; 2001 Mar 01; 9(3):563-73. PubMed ID: 11310590
    [Abstract] [Full Text] [Related]

  • 14. The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypyridin-4-one oral iron chelators.
    Hershko C, Theanacho EN, Spira DT, Peter HH, Dobbin P, Hider RC.
    Blood; 1991 Feb 01; 77(3):637-43. PubMed ID: 1991172
    [Abstract] [Full Text] [Related]

  • 15. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
    Hoyes KP, Jones HM, Abeysinghe RD, Hider RC, Porter JB.
    Exp Hematol; 1993 Jan 01; 21(1):86-92. PubMed ID: 8417963
    [Abstract] [Full Text] [Related]

  • 16. Iron chelators as therapeutic agents against Pneumocystis carinii.
    Weinberg GA.
    Antimicrob Agents Chemother; 1994 May 01; 38(5):997-1003. PubMed ID: 8067783
    [Abstract] [Full Text] [Related]

  • 17. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.
    Porter JB, Singh S, Hoyes KP, Epemolu O, Abeysinghe RD, Hider RC.
    Adv Exp Med Biol; 1994 May 01; 356():361-70. PubMed ID: 7887242
    [No Abstract] [Full Text] [Related]

  • 18. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
    Hoyes KP, Porter JB.
    Br J Haematol; 1993 Oct 01; 85(2):393-400. PubMed ID: 8280612
    [Abstract] [Full Text] [Related]

  • 19. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
    Wong A, Alder V, Robertson D, Papadimitriou J, Maserei J, Berdoukas V, Kontoghiorghes G, Taylor E, Baker E.
    Biometals; 1997 Oct 01; 10(4):247-56. PubMed ID: 9353871
    [Abstract] [Full Text] [Related]

  • 20. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
    Thuma PE, Olivieri NF, Mabeza GF, Biemba G, Parry D, Zulu S, Fassos FF, McClelland RA, Koren G, Brittenham GM, Gordeuk VR.
    Am J Trop Med Hyg; 1998 Mar 01; 58(3):358-64. PubMed ID: 9546419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.